19 Aug, 2024

Which of your patients would you consider for REXULTI®?

Watch Professor Gregory Mattingly as he describes which patients he’s seen benefit from REXULTI® and discusses his experience prescribing it for younger patients and patients early in the disease course.*

*REXULTI® is indicated in adult patients for the treatment of schizophrenia. It is not indicated for patients under the age of 18 years.1

References

1. REXULTI® Approved Product Information.

The views and opinions expressed in this video do not necessarily reflect those of Lundbeck and Otsuka.

Page: AU-ABIM-0583. September 2024. Video: AU-REXU-0387. November 2023.

  • Box
    Body

    REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia

  • text
    Body

    Please review Approved Product Information before prescribing.
    Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:

    REXULTI PI

    REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.

Related

Related

GO TO

Contributor

Dr Gregory Mattingly
MD, Associate Professor Washington University School of Medicine and President, Midwest Group, St. Louis, Missouri, USA

BROUGHT TO YOU BY

Lundbeck
© 2022 Lundbeck Australia

LUNDBECK AUSTRALIA PRODUCTS

Privacy and disclaimer

Cookies

Contact Us

Lundbeck Australia Pty Ltd 
1 Innovation road, Ground floor
NSW 2113, North Ryde, Australia
Phone +61 2 8669 1000
Fax +61 2 8669 1090

 

otsuka logo

 

Otsuka Australia Pharmaceutical Pty. Ltd

subscribe newsletter

Sign up for newsletter

This website is intended for viewing only by health care professionals in Australia.

All information provided within this site is intended only for residents of Australia.